Invesco Ltd. Boosts Stake in KalVista Pharmaceuticals, Inc. $KALV

Key Points

• Invesco Ltd. increased its stake in KalVista Pharmaceuticals by 154.5%, now holding 39,804 shares worth approximately $459,000 as of the latest SEC disclosure.
• Wall Street analysts have raised their price targets for KalVista, with HC Wainwright and JMP Securities both increasing their target to $27.00, reflecting a positive outlook on the company's performance.
• CEO Benjamin L. Palleiko sold 32,979 shares of the company at an average price of $15.69, resulting in an 8.19% decrease in his ownership position.

Invesco Ltd. raised its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 154.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,804 shares of the specialty pharmaceutical company's stock after purchasing an additional 24,164 shares during the quarter. Invesco Ltd. owned 0.08% of KalVista Pharmaceuticals worth $459,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. raised its position in KalVista Pharmaceuticals by 12.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 113,124 shares of the specialty pharmaceutical company's stock valued at $1,305,000 after purchasing an additional 12,776 shares during the period. Vanguard Group Inc. raised its position in KalVista Pharmaceuticals by 1.9% in the first quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company's stock valued at $26,526,000 after purchasing an additional 43,355 shares during the period. Earned Wealth Advisors LLC purchased a new stake in KalVista Pharmaceuticals in the first quarter valued at $44,000. CWM LLC raised its position in KalVista Pharmaceuticals by 12,636.1% in the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company's stock valued at $53,000 after purchasing an additional 4,549 shares during the period. Finally, Emerald Advisers LLC raised its position in KalVista Pharmaceuticals by 7.4% in the first quarter. Emerald Advisers LLC now owns 898,190 shares of the specialty pharmaceutical company's stock valued at $10,365,000 after purchasing an additional 62,140 shares during the period.

Wall Street Analyst Weigh In

KALV has been the subject of a number of research reports. Leerink Partners lifted their price objective on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, July 7th. HC Wainwright lifted their price objective on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. Finally, JMP Securities lifted their price objective on KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a research note on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $26.29.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, CEO Benjamin L. Palleiko sold 32,979 shares of the company's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total transaction of $517,440.51. Following the completion of the transaction, the chief executive officer directly owned 369,595 shares of the company's stock, valued at approximately $5,798,945.55. This represents a 8.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Paul K. Audhya sold 2,942 shares of the company's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.22, for a total value of $38,893.24. Following the transaction, the insider directly owned 119,841 shares of the company's stock, valued at approximately $1,584,298.02. This represents a 2.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 59,710 shares of company stock valued at $880,764 over the last three months. 4.30% of the stock is currently owned by insiders.

KalVista Pharmaceuticals Price Performance

KALV opened at $15.82 on Friday. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $16.32. The stock has a market capitalization of $796.38 million, a price-to-earnings ratio of -4.29 and a beta of -0.10. The business has a fifty day moving average price of $13.79 and a 200 day moving average price of $12.63.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) EPS for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same period in the previous year, the business earned ($1.07) earnings per share. On average, research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

Want to see what other hedge funds are holding KALV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.